PL3347030T3 - Zastosowanie pasteryzowanych bakterii akkermansia w leczeniu zaburzeń metabolicznych - Google Patents

Zastosowanie pasteryzowanych bakterii akkermansia w leczeniu zaburzeń metabolicznych

Info

Publication number
PL3347030T3
PL3347030T3 PL16763806T PL16763806T PL3347030T3 PL 3347030 T3 PL3347030 T3 PL 3347030T3 PL 16763806 T PL16763806 T PL 16763806T PL 16763806 T PL16763806 T PL 16763806T PL 3347030 T3 PL3347030 T3 PL 3347030T3
Authority
PL
Poland
Prior art keywords
metabolic disorders
treating metabolic
pasteurized akkermansia
akkermansia
pasteurized
Prior art date
Application number
PL16763806T
Other languages
English (en)
Inventor
Patrice Cani
Amandine EVERARD
Hubert PLOVIER
Céline DRUART
Willem De Vos
Clara BELZER
Original Assignee
Université Catholique de Louvain
Wageningen Universiteit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54145609&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3347030(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Université Catholique de Louvain, Wageningen Universiteit filed Critical Université Catholique de Louvain
Publication of PL3347030T3 publication Critical patent/PL3347030T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/332—Promoters of weight control and weight loss
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Birds (AREA)
  • Physiology (AREA)
  • Botany (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Cosmetics (AREA)
PL16763806T 2015-09-10 2016-09-09 Zastosowanie pasteryzowanych bakterii akkermansia w leczeniu zaburzeń metabolicznych PL3347030T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15184758 2015-09-10
EP16763806.3A EP3347030B1 (en) 2015-09-10 2016-09-09 Use of pasteurized akkermansia for treating metabolic disorders
PCT/EP2016/071327 WO2017042347A1 (en) 2015-09-10 2016-09-09 Use of pasteurized akkermansia for treating metabolic disorders

Publications (1)

Publication Number Publication Date
PL3347030T3 true PL3347030T3 (pl) 2021-11-22

Family

ID=54145609

Family Applications (3)

Application Number Title Priority Date Filing Date
PL21183989.9T PL3943093T3 (pl) 2015-09-10 2016-09-09 Zastosowanie pasteryzowanej akkermansia do leczenia nowotworu złośliwego
PL19201220T PL3626081T3 (pl) 2015-09-10 2016-09-09 Pasteryzowane bakterie akkermansia w leczeniu zaburzeń metabolicznych
PL16763806T PL3347030T3 (pl) 2015-09-10 2016-09-09 Zastosowanie pasteryzowanych bakterii akkermansia w leczeniu zaburzeń metabolicznych

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PL21183989.9T PL3943093T3 (pl) 2015-09-10 2016-09-09 Zastosowanie pasteryzowanej akkermansia do leczenia nowotworu złośliwego
PL19201220T PL3626081T3 (pl) 2015-09-10 2016-09-09 Pasteryzowane bakterie akkermansia w leczeniu zaburzeń metabolicznych

Country Status (15)

Country Link
US (4) US10736924B2 (pl)
EP (3) EP3626081B1 (pl)
JP (2) JP6954563B2 (pl)
KR (5) KR102581908B1 (pl)
CN (2) CN114276960A (pl)
AU (2) AU2016319221B2 (pl)
BR (1) BR112018004532B1 (pl)
DK (2) DK3347030T3 (pl)
EA (1) EA201800199A1 (pl)
ES (3) ES3031514T3 (pl)
IL (1) IL257978B (pl)
MX (1) MX394909B (pl)
PL (3) PL3943093T3 (pl)
PT (2) PT3347030T (pl)
WO (1) WO2017042347A1 (pl)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014075745A1 (en) 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders
EP4529950A3 (en) 2014-10-31 2025-08-20 Pendulum Therapeutics, Inc. Methods and compositions relating to microbial treatment
EP3292135B1 (en) 2015-05-06 2022-09-21 Wageningen Universiteit Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status
WO2016177682A1 (en) 2015-05-06 2016-11-10 Snipr Technologies Limited Altering microbial populations & modifying microbiota
DK3347030T3 (da) * 2015-09-10 2021-08-09 Univ Catholique Louvain Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme
CA3020454A1 (en) * 2016-04-11 2017-10-19 Wageningen Universiteit Akkermansia glycaniphilus strains
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
CA3211208A1 (en) 2017-04-03 2018-10-11 Gusto Global, Llc Rational design of microbial-based biotherapeutics
TWI636788B (zh) * 2017-08-28 2018-10-01 長庚生物科技股份有限公司 戈氏副擬桿菌用於抑制脂肪肝疾病之用途
WO2019046646A1 (en) 2017-08-30 2019-03-07 Whole Biome Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
CN111527195B (zh) 2017-09-28 2023-11-03 Ko生物技术有限公司 用产生短链脂肪酸的肠道细菌群落的改变诊断和治疗酒精性肝病的组合物
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
AU2019253714A1 (en) 2018-04-10 2020-11-26 Siolta Therapeutics, Inc. Microbial consortia
CN113164526A (zh) 2018-07-19 2021-07-23 潘德勒姆治疗公司 用于微生物植入的方法和组合物
US20250064867A1 (en) * 2018-10-01 2025-02-27 Korea Research Institute Of Bioscience And Biotechnology Method for preventing or treating muscle disease
WO2020071660A1 (ko) * 2018-10-01 2020-04-09 한국생명공학연구원 아커만시아 뮤시니필라 균주 또는 이의 배양물을 유효성분으로 함유하는 노화방지용 조성물
KR102197180B1 (ko) 2018-10-11 2020-12-31 주식회사 고바이오랩 아커만시아 뮤시니필라 균주 및 이를 포함하는 식욕 억제 및 대사성 질환 예방, 개선, 완화 및 치료용 조성물
CN109259240A (zh) * 2018-10-12 2019-01-25 人和未来生物科技（长沙）有限公司 调节肠道菌群和防治肥胖的组合物及其应用
US11851663B2 (en) 2018-10-14 2023-12-26 Snipr Biome Aps Single-vector type I vectors
FR3099054A1 (fr) * 2019-07-24 2021-01-29 Institut National De La Recherche Agronomique (Inra) Souche de Christensenella pour son utilisation dans le traitement et la prévention d’une inflammation gastro-intestinale
KR102263030B1 (ko) * 2019-05-07 2021-06-10 한국생명공학연구원 염증성 장질환의 예방 또는 치료용 펩타이드
KR102128287B1 (ko) * 2019-08-23 2020-06-30 주식회사 엔테로바이옴 아커만시아 뮤시니필라 eb-amdk19 균주 및 그의 용도
KR102128289B1 (ko) * 2019-08-23 2020-06-30 주식회사 엔테로바이옴 아커만시아 뮤시니필라 eb-amdk27 균주 및 그의 용도
CN110679949A (zh) * 2019-09-30 2020-01-14 山东晶辉生物技术有限公司 一种减肥组合物及其制备方法
KR102397916B1 (ko) * 2019-10-01 2022-05-17 (주)헬스바이옴 건강한 임산부 모유 유래 혐기성 인체 균주 및 이를 이용한 대사성 질환의 예방 또는 치료방법
JP7624449B2 (ja) 2019-10-07 2025-01-30 シオルタ・セラピューティクス，インコーポレイテッド 治療用医薬組成物
CN110786376A (zh) * 2019-11-07 2020-02-14 中南大学湘雅医院 嗜黏蛋白艾克曼氏灭活菌在制备酸奶中的应用及酸奶的制备方法和应用
EP4081231A4 (en) * 2019-12-23 2024-01-24 Pendulum Therapeutics, Inc. COMPOSITIONS COMPRISING MICROBES AND METHODS OF USE AND MANUFACTURE THEREOF
WO2021203081A1 (en) * 2020-04-03 2021-10-07 Dupont Nutrition Biosciences Aps Composition comprising eubacterium eligens dsm 33458, intestinimonas massiliensis dsm 33460, prevotella copri dsm 33457 and/or akkermansia dsm 33459
EP4141023A4 (en) 2020-04-24 2024-05-22 Kobiolabs, Inc. PROTEIN VARIANT WITH GLP-1-INDUCING ACTIVITY AND USE THEREOF
KR102309911B1 (ko) 2020-05-11 2021-10-07 재단법인 아산사회복지재단 신규한 아커만시아 뮤시니필라 ak32 균주의 발견 및 장 손상의 예방 또는 치료를 위한 응용
KR102185827B1 (ko) * 2020-08-26 2020-12-03 주식회사 엔테로바이옴 아커만시아 뮤시니필라 균주를 포함하는 아토피성 질환 예방 또는 치료용 약학적 조성물
BE1028330B1 (fr) * 2020-11-09 2021-12-17 A Mansia Biotech Composition comprenant de l'Akkermansia muciniphila et de l'extrait de camu camu
BE1028339B1 (fr) * 2020-11-09 2021-12-21 A Mansia Biotech Composition comprenant de l'Akkermansia muciniphila et de l'extrait de thé vert
CN113041214A (zh) * 2021-03-16 2021-06-29 中南大学湘雅医院 一种负载嗜粘蛋白-艾克曼菌的改性透明质酸水凝胶及其制备方法和应用
CN113116936A (zh) * 2021-04-02 2021-07-16 上海市第六人民医院 嗜黏蛋白艾克曼氏菌在制备β-鹅脱氧胆酸抑制剂中的应用
CN113265359A (zh) * 2021-05-26 2021-08-17 广西壮族自治区兽医研究所 一种改良的嗜黏蛋白阿克曼氏菌液体培养方法
BE1029496B1 (fr) 2021-08-19 2023-01-16 The Akkermansia Company Composition comprenant de l'Akkermansia muciniphila pasteurisée pour le traitement ou la prévention des troubles de la contractilité intestinale, en particulier des troubles de l'amplitude de la contractilité duodénale
BE1029502B1 (fr) 2021-08-19 2023-01-17 The Akkermansia Company Composition comprenant de l'Akkermansia muciniphila pasteurisée pour le traitement ou la prévention de l'anxiété liée au syndrome du côlon irritable
FR3129831B1 (fr) 2021-12-07 2025-04-11 Activinside Utilisation d’une composition à base de Crocus sativus comme prébiotique
US12156859B2 (en) * 2021-12-20 2024-12-03 Tainnovation Inc. Methods of and compositions for treating obesity, obesity-related diseases or cancers using a N6-methyllysine/l-lysine mixture
CN114949003B (zh) * 2022-06-08 2024-03-19 广州知易生物科技有限公司 嗜粘蛋白阿克曼菌及其应用和培养方法
CN114949002B (zh) * 2022-06-08 2024-03-19 广州知易生物科技有限公司 嗜粘蛋白阿克曼菌在制备防治动脉粥样硬化的组合物中的应用
CN115612635B (zh) * 2022-06-23 2024-08-27 济南大学 一种嗜黏蛋白艾克曼菌ww001及其组合物、复合菌剂与应用
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
CN115777625B (zh) * 2022-10-17 2026-04-17 复旦大学 一种建立帕金森病动物模型的方法
CN116270756A (zh) * 2023-02-27 2023-06-23 广州知易生物科技有限公司 嗜黏蛋白阿克曼氏菌及其药物组合物在改善和治疗神经退行性疾病中的应用
CN116617258B (zh) * 2023-07-10 2026-06-30 江南大学 一种治疗溃疡性结肠炎药菌组合物的制备方法及应用
CN116999468B (zh) * 2023-08-18 2024-11-15 善恩康生物科技（苏州）有限公司 Akkermansia muciniphila在制备预防、治疗和/或辅助治疗心血管疾病的产品中的应用
CN116925975B (zh) * 2023-08-18 2024-01-23 善恩康生物科技（苏州）有限公司 一种Akkermansia muciniphila及其产品和应用
CN117482128A (zh) * 2023-09-18 2024-02-02 南京北极光生物科技有限公司 一种含嗜黏蛋白阿克曼菌后生元的组合物及其在糖代谢脂代谢中的应用
WO2025077370A1 (zh) * 2023-10-12 2025-04-17 雷文虎克生物技术股份有限公司 艾克曼嗜黏蛋白菌及其用于预防非酒精性脂肪肝炎的用途
CN118178476A (zh) * 2024-04-03 2024-06-14 暨南大学附属第一医院（广州华侨医院） 阿克曼菌及其制剂在制备促进排便、排脂、减少肠道脂肪吸收的药物中的应用
WO2026096387A1 (en) * 2024-10-30 2026-05-07 Bloom Science, Inc. Probiotics and methods to reduce weight

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050180962A1 (en) * 2003-01-30 2005-08-18 Eyal Raz Inactivated probiotic bacteria and methods of use thereof
DK1931363T3 (en) * 2005-09-28 2016-02-22 Nordisk Rebalance As Treatment of IBD using both probiotic bacteria and fermented cereal as behandlingseffektorer
WO2008076696A2 (en) 2006-12-18 2008-06-26 Washington University In St. Louis The gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder
EP2030623A1 (en) 2007-08-17 2009-03-04 Nestec S.A. Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria
FR2944524B1 (fr) 2009-04-17 2012-11-30 Ipsen Pharma Sas Derives d'imidazolidine-2,4-dione et leur utilisation comme medicament
EP2422200A4 (en) 2009-04-23 2013-02-27 California Inst Of Techn METHOD AND SYSTEMS FOR IDENTIFYING IMMUNOMODULATIVE SUBSTANCES
US8784798B2 (en) * 2009-05-11 2014-07-22 Nestec S.A. Bifidobacterium longum NCC2705 (CNCM I-2618) and immune disorders
EP2251020A1 (en) 2009-05-11 2010-11-17 Nestec S.A. Short-time high temperature treatment generates microbial preparations with anti-inflammatory profiles
EP2524029B1 (en) * 2010-01-15 2018-03-21 The Regents of The University of California Electro-autotrophic synthesis of higher alcohols
EP2449891A1 (en) * 2010-11-05 2012-05-09 Nestec S.A. Drinking yoghurt preparations containing non-replicating probiotic micro-organisms
ES2565407T3 (es) * 2010-11-05 2016-04-04 Nestec S.A. Procedimiento para la preparación de un producto alimenticio para animales de compañía, el cual contiene microorganismos probióticos
US20130287874A1 (en) * 2010-11-11 2013-10-31 Nestec S.A. Spoonable yogurt preparations containing non-replicating probiotic micro-organisms
JP5813976B2 (ja) * 2011-03-29 2015-11-17 ユニ・チャーム株式会社 ペット用おむつ
WO2012170478A2 (en) * 2011-06-06 2012-12-13 The University Of North Carolina At Chapel Hill Methods and kits for detecting adenomas, colorectal cancer, and uses thereof
KR20130021920A (ko) 2011-08-24 2013-03-06 포항공과대학교 산학협력단 Ａｋｋｅｒｍａｎｓｉａ ｍｕｃｉｎｉｐｈｉｌａ 또는 Ｂａｃｔｅｒｏｉｄｅｓ ａｃｉｄｉｆａｃｉｅｎｓ 유래 세포밖 소포체를 유효성분으로 함유하는 염증성 질환의 치료 또는 예방용 조성물
IN2014DN07752A (pl) * 2012-02-29 2015-05-15 Ethicon Endo Surgery Inc
WO2014007606A1 (en) * 2012-07-05 2014-01-09 N.V. Nutricia Product for use in the prophylactic or therapeutic treatment of a negative emotion or introvert behaviour
WO2014019271A1 (en) * 2012-08-01 2014-02-06 Bgi Shenzhen Biomarkers for diabetes and usages thereof
WO2014075745A1 (en) * 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders
WO2014201037A2 (en) * 2013-06-10 2014-12-18 New York University Methods for manipulating immune responses by altering microbiota
EP3285777B1 (en) * 2015-04-23 2021-06-09 Kaleido Biosciences, Inc. Glycan therapeutics and methods of treatment
EP3292135B1 (en) * 2015-05-06 2022-09-21 Wageningen Universiteit Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status
DK3347030T3 (da) * 2015-09-10 2021-08-09 Univ Catholique Louvain Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme
US10537597B2 (en) * 2015-10-05 2020-01-21 Schweizerisches Forschungsinstitut Fur Hochgebrigsklima Und Medizin In Davos Use of Akkermansia muciniphila for treating inflammatory conditions
WO2022002660A1 (en) * 2020-07-01 2022-01-06 Wageningen Universiteit Amuc-1100 polypeptide variants for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status
CN113862193B (zh) * 2021-10-28 2023-12-22 江西普瑞森基因科技有限公司 一株嗜黏蛋白阿克曼氏菌及其在制备抗肿瘤药物中的应用

Also Published As

Publication number Publication date
BR112018004532A2 (pt) 2018-12-11
KR20230125340A (ko) 2023-08-29
CN108289918A (zh) 2018-07-17
JP2022000040A (ja) 2022-01-04
AU2016319221B2 (en) 2022-06-30
CN114276960A (zh) 2022-04-05
CN108289918B (zh) 2022-01-18
IL257978A (en) 2018-05-31
US20180250347A1 (en) 2018-09-06
US20260199407A1 (en) 2026-07-16
EP3626081B1 (en) 2022-02-09
JP2019500004A (ja) 2019-01-10
HK1257222A1 (en) 2019-10-18
PT3626081T (pt) 2022-02-25
KR20220148941A (ko) 2022-11-07
AU2022203731A1 (en) 2022-06-23
EP3347030B1 (en) 2021-07-14
EP3943093C0 (en) 2025-05-07
EP3626081A1 (en) 2020-03-25
BR112018004532B1 (pt) 2022-03-15
KR20240137695A (ko) 2024-09-20
PL3626081T3 (pl) 2022-04-25
KR20180053336A (ko) 2018-05-21
US20210015876A1 (en) 2021-01-21
AU2022203731B2 (en) 2025-02-27
MX394909B (es) 2025-03-24
PL3943093T3 (pl) 2025-09-01
ES2908310T3 (es) 2022-04-28
EP3943093A1 (en) 2022-01-26
US20260166098A1 (en) 2026-06-18
CA2998039A1 (en) 2017-03-16
IL257978B (en) 2021-12-01
ES3031514T3 (en) 2025-07-09
KR102530852B1 (ko) 2023-05-12
PT3347030T (pt) 2021-08-19
KR102569754B1 (ko) 2023-08-23
EP3347030A1 (en) 2018-07-18
JP6954563B2 (ja) 2021-10-27
US10736924B2 (en) 2020-08-11
WO2017042347A1 (en) 2017-03-16
DK3626081T3 (da) 2022-02-28
EA201800199A1 (ru) 2018-12-28
ES2883231T3 (es) 2021-12-07
AU2016319221A1 (en) 2018-03-29
MX2018002990A (es) 2018-06-08
DK3347030T3 (da) 2021-08-09
KR20230070053A (ko) 2023-05-19
EP3943093B1 (en) 2025-05-07
KR102581908B1 (ko) 2023-09-22

Similar Documents

Publication Publication Date Title
IL257978A (en) Use of pasteurized acrementia to treat metabolic diseases
IL285151B1 (en) Methods for the treatment of fgf21-related disorders
IL251066B (en) Preparations and methods for the treatment of metabolic disorders
ZA201700311B (en) Compositions and methods of use for treating metabolic disorders
PL3261726T3 (pl) Kompozycja do leczenia trądziku
IL258593B (en) Compounds for the treatment of subculture disorders
PT3164123T (pt) Novas utilizações terapêuticas de derivados de benzilidenoguanidina para o tratamento de proteopatias
GB201612043D0 (en) Composition for treatment of disorders
GB201408387D0 (en) Treatment of respiratory disorders
GB201607388D0 (en) Treatment of impulsivity-related disorders
SG11201708181RA (en) Methods for the treatment of inflammatory disorders
SG11201708198SA (en) Methods for the treatment of cardiovascular disorders
EP3200795A4 (en) Use of agents for treating fat-related disorders
GB201516418D0 (en) Treatment of acute inflammatory disorders
GB201602784D0 (en) New treatment of CFTR-related disorders
GB201506228D0 (en) Methods For The Treatment Of Cardivascular Disorders
GB201521542D0 (en) Methods for the treatment of cardiovascular disorders
GB201521543D0 (en) Methods for the treatment of inflammatory disorders
GB201516140D0 (en) Treatment of acute inflammatory disorders
GB201513991D0 (en) Methods for the treatment of cardiovascular disorders
GB201513344D0 (en) Methods for the treatment of Cardiovascular disorders
GB201513993D0 (en) Methods for the treatment of inflammatory disorders
GB201513345D0 (en) Methods for the treatment of Inflammatory disorders
GB201507109D0 (en) Methods for the treatment of cardiovascular disorders
GB201507113D0 (en) Methods for the treatment of inflammatory disorders